1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

Thumbnail for Long-Term Hematologic Control and Safety in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Iptacopan: 6-Year Follow-Up From Phase 2 Studies and Roll-Over Extension Program

MDS - 1167

Long-Term Hematologic Control and Safety in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Iptacopan: 6-Year Follow-Up From Phase 2 Studies and Roll-Over Extension Program

Nick Kuypers

Poster Presenter: Nick Kuypers

$Thumbnail for Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial$

MM - 1168

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Robert Rifkin

Poster Presenter: Robert Rifkin

SOHO 2026 Annual Meeting

Posters by Session

Long-Term Hematologic Control and Safety in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Iptacopan: 6-Year Follow-Up From Phase 2 Studies and Roll-Over Extension Program

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Novel Interventions for Gastrointestinal Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan for Autologous Stem Cell Transplantation: A Systematic Review

Risk Stratification of Acute Kidney Injury in Waldenstrφm Macroglobulinemia: Machine Learning-Derived Clinical Phenotypes From a National Inpatient Database

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenstrφm Macroglobulinemia: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies

Comparative Outcomes of CAR-T Versus Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma: A TriNetX Network Analysis

Infectious Morbidity with Bispecific T Cell Engager Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Synthesis Revealing a Preventable Survival Gap

Comparative Outcomes of Haploidentical and Matched Donor Stem Cell Transplantation Versus Autologous Transplantation in Hematologic Malignancies: A Meta-Analytic Synthesis

CALGB 10403 in Latin America: A Single-Center Study with Extended Follow-Up